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Close homolog of L1 (CHL1) is a member of the L1
family of cell adhesion molecules expressed by subpopu-
lations of neurons and glia in the central and peripheral
nervous system. It promotes neurite outgrowth and neu-
ronal survival in vitro. This study describes a novel
function for CHL1 in potentiating integrin-dependent
cell migration toward extracellular matrix proteins. Ex-
pression of CHL1 in HEK293 cells stimulated their hap-
totactic migration toward collagen I, fibronectin, lami-
nin, and vitronectin substrates in Transwell assays.
CHL1-potentiated cell migration to collagen I was de-
pendent on 11 and 21 integrins, as shown with func-
tion blocking antibodies. Potentiated migration relied
on the early integrin signaling intermediates c-Src,
phosphatidylinositol 3-kinase, and mitogen-activated
protein kinase. Enhancement of migration was dis-
rupted by mutation of a potential integrin interaction
motif Asp-Gly-Glu-Ala (DGEA) in the sixth immunoglob-
ulin domain of CHL1, suggesting that CHL1 functionally
interacts with 1 integrins through this domain. CHL1
was shown to associate with 1 integrins on the cell
surface by antibody-induced co-capping. Through a cy-
toplasmic domain sequence containing a conserved ty-
rosine residue (Phe-Ile-Gly-Ala-Tyr), CHL1 recruited the
actin cytoskeletal adapter protein ankyrin to the plasma
membrane, and this sequence was necessary for promot-
ing integrin-dependent migration to extracellular ma-
trix proteins. These results support a role for CHL1 in
integrin-dependent cell migration that may be physio-
logically important in regulating cell migration in nerve
regeneration and cortical development.
In vertebrates, the L1 family of cell adhesion molecules
(CAMs)1 is comprised of four members: L1/NgCAM, close hom-
olog of L1 (CHL1), neurofascin, and NrCAM, all serving mul-
tiple functions in the development and function of the nervous
system. L1, the prototype of this family of transmembrane
glycoproteins, has been shown to participate in cell migration,
axon fasciculation, and guidance, as well as synaptogenesis
and adult synaptic plasticity (1). The importance of L1 function
in human brain development is revealed by the association of
mutations in the L1 gene with a syndromic form of mental
retardation, the L1 syndrome, formerly named CRASH (corpus
callosum agenesis, mental retardation, adducted thumbs, spas-
ticity, and hydrocephalus) (2–4). L1 knockout mice display
nervous system anomalies similar to those seen in human
patients, although there appear to be additional genetic modi-
fiers of the disease (5–8).
L1 family members share a structural plan consisting of an
extracellular region comprised of six Ig-like domains, four or
five fibronectin type III domains, a single transmembrane seg-
ment, and a short, conserved cytoplasmic region (9). The extra-
cellular portion of these proteins is highly glycosylated and
allows them to participate in both homophilic and heterophilic
interactions with a variety of ligands, including other members
of the Ig superfamily. The cytoplasmic domain of L1 family
members interacts with components of the actin cytoskeleton
(10), protein kinases (11–13), and complexes associated with
endocytosis and protein trafficking in a lipid raft-associated
manner (14, 15). An important binding partner is ankyrin, a
protein that binds to the subcortical actin/spectrin cytoskeleton
(16, 17). The interaction of L1 with ankyrin occurs through a
conserved FIGQY sequence (Phe-Ile-Gly-Gln-Tyr) within the
cytoplasmic domain and is proposed to stabilize axonal mem-
branes and/or intercellular connections (18). This idea is sup-
ported by the finding that in mice lacking ankyrin B, the axons
eventually degenerate (19), although initial axon outgrowth
and L1 targeting are relatively normal.
CHL1 is a newly identified member of the L1 family that is
expressed in subpopulations of developing neurons in the cen-
tral and peripheral nervous systems and that persists at low
levels in the mature brain in areas of high plasticity (20, 21).
CHL1 is also expressed by Schwann cells, astrocytes, and oli-
godendrocyte precursors (22) and is strikingly up-regulated in
Schwann cells and sensory neurons upon nerve crush injury
(23). The CALL gene, the human ortholog of the CHL1 gene
(24), is closely linked to the 3p syndrome characterized by
mental retardation (25). The human CHL1 gene is mutated in
a patient with mental retardation (26). An increased risk for
schizophrenia associated with a missense polymorphism has
also been reported (27). A recent study (28) showed that CHL1-
deficient mice display misguided axons within the hippocam-
pus and olfactory tract and anomalies in behavior. These find-
ings emphasize the importance of CHL1 in the nervous system,
although its specific functions are yet unknown.
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CHL1 shares the basic structural plan of L1 family members
(22) and has strong neurite outgrowth promoting capacity (20).
The sequence of CHL1 reveals 60% amino acid identity with
L1 in the extracellular region and 40% identity in the cyto-
plasmic domain. Yet in contrast to L1, CHL1 is not capable of
self-associating, nor does it bind heterophilically to L1, and an
extracellular domain-binding partner remains to be found (20).
The extracellular segment of CHL1 contains a potential inte-
grin-binding motif Arg-Gly-Asp (RGD) in the second Ig-like
domain, where it may be masked by the predicted horseshoe
conformation of the molecule (29, 30), rather than within the
sixth Ig-like domain as in L1. However, the sixth Ig domain of
CHL1 contains another potential integrin interaction motif
Asp-Gly-Glu-Ala (DGEA), which has been reported to mediate
integrin-collagen interactions in platelets (31). Finally, CHL1
is the only L1 family member with an altered sequence
(FIGAY) in the presumed ankyrin-binding domain, and it lacks
the RSLE motif, which is characteristic of other family mem-
bers and is involved in endocytosis.
The structural resemblance and the differences between
CHL1 and the other members of the L1 family of CAMs suggest
that this molecule might have both similar and distinctive
functions within cells. Recently it was shown that L1 promotes
integrin-mediated haptotactic migration of cultured cells to-
ward extracellular matrix proteins (32–37). Because of poten-
tial integrin interaction motifs in CHL1, it was speculated that
CHL1 may have a role in integrin-mediated cell migration.
Here it is shown that CHL1 promotes haptotactic cell migra-
tion toward extracellular matrix proteins, but this function
differs from L1 in regard to preference of extracellular matrix
substrate and integrin partners. These differences are related
to the structural differences between CHL1 and L1 and may
be important for differentially regulating cell migration during
nerve regeneration and neuronal migration during
development.
EXPERIMENTAL PROCEDURES
Plasmids and Reagents—The following cDNAs were subcloned into
pcDNA3 (Stratagene, La Jolla, CA): wild type mouse CHL1, a CHL1
mutant in which the RGD sequence in the Ig2 domain was mutated to
KGE, a CHL1 mutant in which the DGEA sequence in the Ig6 domain
was mutated to AGEV, a CHL1 mutant in which the cytoplasmic
sequence FIGAY was mutated to FIGAA, and human wild type L1
(RSLE) (from J. Hemperly, BD Technologies, Research Triangle Park,
NC). A plasmid encoding ankyrin G fused to green fluorescent protein
(ankyrin-GFP) was provided by Vann Bennett (Duke University,
Durham, NC). A rabbit polyclonal antibody was made against mouse
CHL1-Fc (22). Mouse monoclonal antibody Neuro4 against an extracel-
lular epitope of human L1 was a gift of J. Hemperly. The following
antibodies were obtained from Chemicon (Temecula, CA): anti-human
1 integrin monoclonal antibody 2253Z (clone 6s6), an activating mono-
clonal antibody MAB2000 (clone HB1.1) against human 1 integrin,
anti-human 1 integrin monoclonal antibody 1973Z (clone FB12), and
anti-human 2 integrin monoclonal antibody 1950Z (clone P1E6). Non-
immune mouse IgG was from Jackson ImmunoResearch Laboratories
(West Grove, PA). Human vitronectin, human fibronectin, and murine
laminin were from Invitrogen and Peninsula Laboratories (San Carlos,
CA). BD Biosciences (Palo Alto, CA) provided type I collagen from rat
tail. MEK inhibitor U0126 (Promega, Madison, WI), Src inhibitor PP2
and inactive analog PP3, and PI 3-kinase inhibitor Ly294002 (CalBio-
chem, San Diego, CA) were dissolved in Me2SO.
Cell Culture and Haptotactic Migration Assay—HEK293 cell cul-
tures were maintained in Dulbecco’s modified Eagle’s medium (DMEM)
(Mediatech Cellgro), 4.5 mg/ml glucose, 10% heat-inactivated fetal bo-
vine serum, 50 g/ml gentamicin, and 250 g/ml kanamycin. Cultures
at 80–90% confluence in 60-mm dishes were transfected for transient
expression of CHL1 or L1 pcDNA3 plasmids (5 g) using Lipofect-
AMINE 2000 (Invitrogen) in Opti-MEM I (Invitrogen). After 18–24 h at
37 °C, the transfected cells were used for haptotactic migration or
ankyrin recruitment assays.
Haptotactic migration of HEK293 cells transiently expressing CHL1
or L1 was assayed essentially as previously reported (37), using modi-
fied Boyden chambers with 8-m pore filters (Transwells 3422, Corn-
ing/Costar, Acton, MA) in serum-free medium (DMEM, 0.4 mM MnCl2,
50 g/ml gentamicin, 250 g/ml kanamycin). In the absence of Mn2,
CHL1 potentiated haptotactic migration of HEK293 cells toward colla-
gen I (1.9-fold) to nearly the same extent as in the presence of Mn2
(2.3-fold). The bottom sides of the filters were precoated with extracel-
lular matrix proteins (500 l of 20 g/ml) or 2% bovine serum albumin
in PBS at 4 °C overnight and blocked in 2% bovine serum albumin. The
cells were detached with 5 mM Na-EDTA in Hanks’ balanced saline
solution (HBSS) and plated at 20,000 cells/Transwell. In some experi-
ments, the cells were preincubated in serum-free medium with anti-
integrin antibodies (1–4 g/ml) for 15–30 min at 4 °C prior to plating.
The cells were allowed to migrate for 3–8 h at 37 °C in a CO2 incubator.
After migration cultures were fixed in 4% paraformaldehyde, rinsed in
PBS, and then treated with blocking solution (10% goat serum, 0.2%
fish skin gelatin, PBS) for either 1 h at room temperature or overnight
at 4 °C.
To score migration, cells from the upper or lower sides of filters were
removed, and cells on the opposite side were stained by indirect immu-
nofluorescence with purified CHL1 polyclonal antibodies (20 g/ml) or
L1 monoclonal antibody Neuro4 (5 g/ml) in blocking solution for 4 h at
room temperature, followed by fluorescein isothiocyanate-conjugated
secondary antibodies (Jackson ImmunoResearch Laboratories) diluted
1:75 to 1:100 in blocking solution. The cells were counterstained with 10
M bis-benzimide (Hoechst 33258; Molecular Probes, Eugene, OR).
The filters were mounted with Vectashield (Vector Laboratories,
Burlingame, CA) on glass slides, and the cells were scored on both top
and bottom surfaces of filters under epifluorescence illumination. For
each filter, at least 150 cells were scored from six or more randomly
selected fields using a 20 objective. To obtain the total number of cells
on each side of a filter, the mean number of cells/field was determined
and multiplied by a factor based on the number and size of fields and a
filter diameter of 6.5 mm. The percentage of CHL1-immunoreactive
cells that transmigrated was calculated as the ratio of CHL1-positive
cells on the bottom of filters to total (top and bottom) CHL1-
positive cells. The percentage of CHL1-negative bis-benzimide-positive
cells that transmigrated was determined similarly. The percentage of
cells transmigrated was converted to the total number of cells migrated
per Transwell by multiplying the percentage by the number of cells
plated. The experiments were performed in duplicate or triplicate, and
the results of each condition were averaged. The means and standard
errors were determined for each condition. Significant differences be-
tween experimental groups was evaluated by Student’s t test (p  0.05,
one-tailed). Transfection efficiency of HEK293 cells was determined as
the number of fluorescein isothiocyanate-labeled cells (transfected)
divided by the number of bis-benzimide-labeled cells (transfected plus
nontransfected) and was 50–70%. There was no deleterious effect of
integrin antibodies or inhibitors on cell adhesion, which was evaluated
by counting the total number of cells recovered after each assay.
Similarly, inhibitors used at concentrations indicated in the signaling
experiments (PP2, PP3, Ly294002, and U0126) did not affect the
viability or cell recovery.
Co-capping Experiments—HEK293 cells transfected with the
pcDNA3-CHL1 plasmid were dissociated in 5 mM EDTA in HBSS,
washed with 10% fetal bovine serum in DMEM, and resuspended in
DMEM. The cells (30,000 cells/100 l) were incubated with anti-inte-
grin 1 mouse monoclonal antibody MAB2000 (20 g/ml) at 4 °C for 20
min. The cells were washed with ice-cold HBSS, resuspended in DMEM
containing 5 g/ml goat anti-mouse IgG (Fc fragment-specific), and
incubated for 20 min at 4 °C. After washing in ice-cold HBSS, the cells
were resuspended in 10% fetal bovine serum in DMEM, plated onto
collagen-coated MatTek plates (MatTek Corp., Ashland, MA), and in-
cubated for 1 h at 37 °C to allow integrins to cluster. The cells were then
fixed in 4% paraformaldehyde in PBS for 15 min, washed, and blocked
with 10% donkey serum in PBS for 1 h at room temperature. To label
CHL1, the cells were incubated with CHL1 rabbit polyclonal antibody
(20 g/ml in blocking buffer) for 2 h at room temperature, washed with
PBS, and then incubated for 1 h at room temperature with fluorescein
isothiocyanate-conjugated donkey anti-rabbit IgG and TRITC-conju-
gated donkey anti-goat IgG diluted 1:100 in blocking buffer. Finally, the
cells were rinsed, mounted in Vectashield, and examined using an
Olympus FV500 laser confocal microscope at the Microscopy Service
Laboratory (Dr. Robert Bagnell, Department of Pathology, University of
North Carolina-Chapel Hill) using appropriate filter sets.
Assay for Ankyrin Recruitment—Ankyrin recruitment to CHL1 in the
plasma membrane was assayed essentially as previously described for
L1 (38) with the following modifications. HEK293 cells on poly-D-lysine-
coated MatTek dishes were transfected with plasmid pEGFP-N1 ex-
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pressing a fusion protein between ankyrin G and green fluorescent
protein (ankyrin-GFP) (0.05 g) with or without co-transfection of
pcDNA3-CHL1 (0.1 g) using LipofectAMINE 2000. After 24 h, the cells
were fixed with 4% paraformaldehyde in 0.1 M phosphate buffer, pH 7.4,
for 15 min, washed, and incubated with blocking buffer (10% normal
goat serum in PBS) for 30 min. To label CHL1 on the cell surface, the
cells were incubated for 4 h at room temperature with rabbit polyclonal
antibody against CHL1 (20 g/ml in blocking buffer), then washed, and
incubated for 2 h with TRITC-conjugated goat anti-rabbit IgG diluted
1:200 in blocking buffer. The cells were washed and mounted in
Vectashield. GFP/immunofluorescence images were recorded on an
Olympus FV500 laser confocal microscope. The ankyrin-GFP fluores-
cence was recorded using the 488-nm excitation line of the laser,
whereas the TRITC-labeled CHL1 was examined using the 543-nm
excitation line of the laser and the appropriate band pass filters. Each
experiment was repeated four times.
RESULTS
CHL1 Potentiates Haptotactic Cell Migration to Extracellu-
lar Matrix Proteins through 1 Integrins—Extracellular matrix
proteins are important in mediating cell migration and neuro-
nal process growth in the developing nervous system (39) and
are implicated in nerve response to injury (40, 41). The ability
of CHL1 to promote haptotactic migration toward extracellular
matrix proteins was studied in Transwell assays in which cells
were allowed to migrate from top to bottom chambers through
filters coated on the underside with purified matrix molecules
(37). The human embryonic kidney cell line HEK293 was used
for these studies, because it expresses defined integrin sub-
units including 1, 2, 3, 5, v, and 1, which can serve as
extracellular matrix protein receptors (42, 43), and because it
does not express detectable levels of cell adhesion molecules of
the L1 family (38). HEK293 cells were transfected for transient
expression with pcDNA3 plasmids encoding CHL1 or L1, and
haptotactic migration was assayed toward purified matrix pro-
teins. Nontransfected HEK293 cells displayed greater migra-
tion toward collagen type I, fibronectin, and laminin compared
with random migration toward bovine serum albumin but did
not migrate significantly toward vitronectin (Fig. 1). Expression
of CHL1 significantly enhanced haptotactic migration toward
each of these substrates as well as to vitronectin (Fig. 1). In
contrast to CHL1, L1 was clearly not capable of enhancing
HEK293 cell migration to collagen I, similar to previous findings
in rat B35 neuroblastoma cells (37), although L1 was as effective
as CHL1 at potentiating cell migration to fibronectin (Fig. 1).
These results showed that CHL1 can promote haptotactic cell
migration toward a range of ECM substrates and suggested that
CHL1 might functionally interact with integrins.
To determine whether integrins were involved in CHL1-
mediated migration, haptotactic migration of HEK293 cells
toward collagen I was further evaluated in the presence of
function-blocking integrin antibodies. Collagen I was chosen as
a substrate, because collagen I, in addition to collagens III and
IV, increases at the site of nerve injury and promotes Schwann
cell migration (41), and CHL1 is up-regulated in Schwann cells
during peripheral nerve regeneration (20, 23). Treatment of
cells with function-blocking 1 integrin antibodies (44) strongly
inhibited CHL1-mediated HEK293 cell migration toward col-
lagen I, as well as CHL1-independent migration of HEK293
cells (Fig. 2). Residual migration of CHL1-HEK293 cells in the
presence of anti-1 integrin antibodies was low but signifi-
cantly elevated over that of HEK293 cells (p  0.05), suggest-
ing that CHL1 might function to a small extent through a
non-1 containing collagen receptor. Because the principal col-
lagen I receptors are known to be 11 and 21 integrins (45),
function-blocking antibodies against 1 and 2 integrins were
evaluated next for effects on migration. Antibodies against
either 1 or 2 integrin strongly inhibited CHL1-mediated mi-
gration toward collagen I, whereas 1 and 2 integrin antibod-
ies added together were as effective as 1 integrin antibodies
(Fig. 2). The 1 and 2 integrin antibodies were not as effective
as 1 integrin antibodies in inhibiting the basal migration of
HEK293 cells, thus it is likely that these cells use 11 and
21 integrins in addition to an unidentified 1 integrin het-
erodimer for migration to collagen. In summary, these results
indicated that CHL1 potentiated the migration of HEK293
cells toward collagen I primarily through 11 and 21
integrins.
The DGEA Motif in the CHL1 Ig6 Domain Is Required for
Potentiating Migration to Collagen I—The mouse CHL1 and
human CALL proteins contain a conserved Asp-Gly-Glu-Ala
(DGEA) motif in the Ig6 domain of their extracellular regions
(22, 24). Interestingly, the DGEA motif is also present in col-
lagen I where it serves as a recognition site for 21 integrin in
platelets (31). Mutation of the DGEA sequence in the CHL1 Ig6
domain to Ala-Gly-Glu-Val (AGEV) effectively inhibited CHL1-
potentiated migration of HEK293 cells toward collagen I, re-
ducing migration to nearly the level of CHL1-nonexpressing
HEK293 cells (Fig. 3). In the Ig6 domain of L1, an Arg-Gly-Asp
(RGD) sequence is required for potentiating migration to fi-
FIG. 1. CHL1 potentiates haptotactic migration of HEK293
cells to extracellular matrix proteins. Haptotactic cell migration
toward extracellular matrix proteins or random migration toward bo-
vine serum albumin was measured in HEK293 cells transiently ex-
pressing CHL1, L1, or expressing no L1 family adhesion molecule for
8 h. The samples were assayed in triplicate, and the experiments were
repeated at least twice with similar results. *, statistically significant
differences in means of transfected (expressing CHL1 or L1) versus
nontransfected cells using the t test (p  0.05).
FIG. 2. CHL1 potentiates migration of HEK293 cells through 1
integrins. Haptotactic migration of CHL1-expressing or nonexpressing
HEK293 cells was measured for 3 h toward collagen I. Cells migrating
toward collagen I were pretreated with nonimmune mouse IgG (Con-
trol; 30 g/ml), integrin 1 antibody (Anti-1; 30 g/ml), integrin 1
antibody (Anti-1; 15 g/ml), integrin 2 antibody (Anti-2; 15 g/ml), or
both antibodies (Anti-1  Anti-2; 30 g/ml). The samples were as-
sayed in triplicate, and the experiments were repeated at least twice
with similar results. *, statistically significant differences in means of
treated versus control samples using the t test (p  0.05). BSA, bovine
serum albumin.
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bronectin (37). The Ig2 domain of CHL1 contains an Arg-Gly-
Asp (RGD) motif (22), and a corresponding sequence (Lys-Gly-
Asp) in the human CALL protein is closely conserved though
nonidentical (24). This motif might interact with integrins,
because RGD is a known adhesion motif that is present in
collagen I, fibronectin, and vitronectin, and it is recognized by
at least eight integrins (46). However, mutation of the RGD in
the CHL1 Ig2 domain to Lys-Gly-Glu (KGE) did not perturb
CHL1-potentiated migration to collagen (Fig. 3). These results
illustrated the importance of the DGEA sequence in the CHL1
Ig6 domain in mediating haptotactic migration toward collagen
I through 1/2 1 integrins.
CHL1 Enhances Migration through c-Src, PI 3-Kinase, and
MAP Kinase—The nonreceptor tyrosine kinase c-Src, PI 3-ki-
nase, and MAP kinase are key signaling intermediates down-
stream of cell adhesion molecules such as L1 (47, 48). There is
evidence that PI 3-kinase also has a role in integrin receptor
recycling (49), whereas MAP kinase has well characterized
functions in regulating cell migration through regulating new
protein synthesis that may be required for synthesis of recep-
tors (50, 51). It is not known whether CHL1 stimulates signal-
ing pathways such as those utilized by L1 in potentiating
haptotactic migration through integrins. To determine whether
Src was required for haptotactic cell migration to collagen I,
HEK293 cells and CHL1-HEK293 cells were treated with PP2,
a pyrazolopyrimidine inhibitor of Src family tyrosine kinases.
PP2, but not its inactive analog, PP3, is a selective inhibitor of
Src family catalytic activity (52). PP2 was a potent inhibitor of
CHL1-dependent migration of HEK293 cells to collagen I,
whereas PP3 had no effect (Fig. 4). PP2 also reduced basal
migration of nonexpressing HEK293 cells, whereas PP3 did
not. To assess the involvement of PI 3-kinase, HEK293 cells
and CHL1-HEK293 cells were treated with the PI 3-kinase
inhibitor LY294002. LY294002 partially inhibited CHL1-de-
pendent migration of HEK293 cells to collagen, indicating that
PI 3-kinase also participated in the CHL1 response (Fig. 4), but
it had no effect on basal migration. To assess the role of MAP
kinase in haptotactic migration, the cells were treated with an
inhibitor (U0126) of the dual specificity kinase MEK, which
normally phosphorylates and activates MAP kinase. The MEK
inhibitor selectively suppressed migration of CHL1-expressing
cells, indicating that MAP kinase was required for the ability of
CHL1 to potentiate haptotactic migration through 1/2 1
integrins to collagen I (Fig. 4). Thus, CHL1 appeared to pro-
mote integrin-mediated haptotactic migration to collagen I
through the signaling intermediates Src and MAP kinase and
to a lesser extent through PI 3-kinase.
CHL1 Co-caps with 1 Integrins on the Cell Surface—Be-
cause these results showed that CHL1 promoted cell migration
toward collagen mediated by integrins, we investigated
whether CHL1 and 1 integrins were laterally associated
within the plasma membrane on the same cell by co-capping
experiments (53). Monoclonal antibody MAB2000 specific for
1 integrins was used to cross-link 1 integrins on the surface
of CHL1-expressing HEK293 cells. Formation of integrin caps
was observed as a cluster of fluorescent spots on the cell surface
(Fig. 5A). CHL1 expression was detected on the same cells by
indirect immunofluorescence staining with CHL1 polyclonal
antibodies (Fig. 5B). The overlay image showed CHL1 co-local-
ization within the integrin cap (Fig. 5C), suggesting that these
proteins were associated either directly or indirectly in cis
within the plasma membrane. CHL1 immunofluorescence
staining did not co-localize with all of the 1 integrin staining,
consistent with the interpretation that CHL1 interacted with a
subset of 1 integrins, most likely only the 11 and 21
subclasses. Integrin caps were formed under these conditions
on the majority of cells, and CHL1 co-localized with the inte-
grin caps on all CHL1-expressing cells. In control assays, non-
immune mouse IgG did not induce integrin capping or CHL1
clustering. Interestingly, mutation of the DGEA sequence in
the Ig6 domain of CHL1 to AGEV did not perturb its ability to
co-cap with 1 integrins (data not shown), thus indicating that
the DGEA motif was neither necessary nor sufficient for the
association between CHL1 and 1 integrins on the cell surface.
The FIGAY Motif in the CHL1 Cytoplasmic Domain Is Re-
quired for Ankyrin Recruitment and Potentiating Migra-
tion—L1 family members are coupled to the actin cytoskeleton
in part through interaction of the intracellular cytoskeletal
adapter protein ankyrin with the sequence Phe-Ile-Gly-Gln-
Tyr (FIGQY), which is conserved in the cytoplasmic domains of
L1, NrCAM, NgCAM, and neurofascin (16, 54) as well as in the
single L1 homolog LAD-1 in Caenorhabditis elegans (55) and
FIG. 3. CHL1 mutations in extracellular Ig6 (DGEA) and cyto-
plasmic (FIGAY) domains suppress CHL1-potentiated migra-
tion to collagen. HEK293 cells transiently expressing wild type
CHL1, CHL1 with mutations DGEA3 AGEV, RGD3 KGE, FIGAY3
FIGAA, or no CHL1 were assayed for haptotactic migration to collagen
I for 3 h. Each sample was assayed in triplicate, and the experiments
were repeated at least twice with similar results. *, statistically signif-
icant differences in means compared with CHL1 wild type (WT) using
the t test (p  0.05).
FIG. 4. c-Src, PI 3-kinase, and MAP kinase are required for
CHL1-potentiated migration of HEK293 cells. Migration of CHL1-
expressing or nonexpressing HEK293 cells was measured toward col-
lagen I for 3 h. Cells migration was conducted in the presence of 0.05%
dimethyl sulfoxide (DMSO, control), Src family inhibitor PP2 (5 M),
PP3 (5 M), an inactive analog of PP2, PI 3-kinase inhibitor LY294002
(25 M), or MEK inhibitor U0126 (15 M). Each sample was assayed in
triplicate, and the experiments were repeated at least twice with sim-
ilar results. *, statistically significant differences in means of treated
and untreated (control) cells using the t test (p  0.05).
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Drosophila neuroglian (56, 57). Although the structure of
CHL1 reveals conservation of most of the functional domains
found in other L1 family members (22), the cytoplasmic domain
of CHL1 bears a nonconservative amino acid substitution in
the putative ankyrin interaction motif, resulting in the se-
quence Phe-Ile-Gly-Ala-Tyr (FIGAY). To examine whether
CHL1 was able to bind ankyrin, a cellular ankyrin recruitment
assay was carried out as described (38, 58) using transfected
HEK293 cells transiently expressing CHL1 and an ankyrin G
fusion protein tagged with green fluorescent protein (ankyrin-
GFP). In this assay, the interaction of ankyrin-GFP with CHL1
in the plasmalemma was detected indirectly through the re-
cruitment of the ankyrin-GFP fluorescent protein from the
cytosol to the cell membrane visualized by confocal microscopy.
When HEK293 cells were transfected with the ankyrin-GFP
plasmid in the absence of CHL1, the fluorescent ankyrin-GFP
fusion protein remained cytosolic and was not recruited to the
plasma membrane (Fig. 6, A and B) possibly as a result of
saturation of binding sites by endogenous ankyrin (58). In
contrast, when HEK293 cells were co-transfected with plas-
mids expressing ankyrin-GFP and CHL1, ankyrin-GFP was
redistributed to the plasma membrane, where CHL1 was
localized (Fig. 6, C–E). The cells shown in panels C–H of Fig.
6 were more sparsely plated than those in panels A and B and
were not in contact with other cells throughout most of their
cell surfaces. The recruitment of ankyrin to the plasma mem-
brane of HEK293 cells by CHL1 appeared to be independent
of cell-cell adhesion, thus differing from L1, which binds
ankyrin in a cell contact-dependent manner in Drosophila S2
cells (56). This may be due to differences in the levels of
CHL1 expression or phosphorylation state or to the unique
structural features of CHL1. These results showed that
CHL1, like the other members of the L1 family, was able to
bind ankyrin. No proteins cross-reacting with the anti-mouse
CHL1 antibody were detected in this human cell line by
Western blot or indirect immunofluorescence analysis (data
not shown).
Mutation of the tyrosine residue within the FIGQY motif of
the cytoplasmic domain of L1 family members disrupts their
ability to recruit ankyrin (38, 54). Mutation of tyrosine 1229 in
L1 to histidine occurs in some patients with the L1 mental
retardation syndrome (59) and may contribute to the patho-
genic mechanism of the disease because of its inability to bind
ankyrin (38). The tyrosine residue contained within the FIGQY
motif of L1 and other family members appears to have a reg-
ulatory capability because it undergoes reversible phosphoryl-
ation by an unidentified kinase that modulates binding to
ankyrin and the microtubule-associated protein doublecortin
(60). To investigate whether the corresponding residue Tyr1186
in the FIGAY sequence of the CHL1 cytoplasmic domain was
essential for ankyrin binding, this residue was mutated to
alanine, and the resulting CHL1 mutant was evaluated for the
ability to recruit ankyrin in the cytofluorescence assay. When
co-expressed with ankyrin-GFP, the mutant FIGAA failed to
recruit fluorescent ankyrin-GFP to the plasma membrane
(Fig. 6, F–H). The CHL1 FIGAA mutant was expressed at a
level similar to that of the wild type CHL1 protein and was
normally inserted in the plasmalemma of HEK293 cells
(Fig. 6H).
To determine whether ankyrin binding by CHL1 and, in
particular, the Tyr1186 residue within the FIGAY sequence
were important for haptotactic migration to extracellular ma-
trix substrates, wild type CHL1 and the FIGAA mutant were
compared for their ability to promote migration of HEK293
cells to collagen I. When the CHL1 FIGAY sequence was mu-
tated to FIGAA, CHL1-potentiated migration was reduced to
the level of HEK293 cells not expressing CHL1 (Fig. 3). Muta-
tion of the CHL1 FIGAY motif to FIGAA did not affect co-
capping with 1 integrins (not shown). These results suggested
that CHL1-potentiated cell migration to extracellular matrix
proteins may be mediated by physical linkage of its cytoplasmic
domain to the actin cytoskeleton through its interaction with
ankyrin and that the Tyr1186 residue was crucial for this
interaction.
DISCUSSION
This study describes a novel function for CHL1 in potentiat-
ing integrin-dependent cell migration toward extracellular ma-
trix proteins. CHL1-potentiated migration of HEK293 cells to
collagen I was dependent on 11 or 21 integrins and was
mediated by early integrin signaling intermediates c-Src, PI
3-kinase, and MAP kinase. Co-capping studies demonstrated
that CHL1 and 1 integrins were capable of associating on the
FIG. 5. 1 integrin and CHL1 co-cap on the surface of CHL1-
expressing HEK293 cells. A, 1 integrin capping (red) was induced by
cross-linking with 1 integrin monoclonal antibody MAB2000 and was
detected with a TRITC-labeled secondary antibody. B, CHL1 protein
(green) labeled with CHL1 polyclonal antibodies and fluorescein isothio-
cyanate-labeled secondary antibody was recruited to the integrin cap.
C, partial co-localization of 1 integrin and CHL1 was indicated by the
yellow color in the overlay image.
FIG. 6. CHL1 is able to recruit ankyrin to the cell membrane
through the FIGAY sequence. HEK293 cells were transfected with
the ankyrin-GFP expression plasmid alone (A and B) or together with a
second plasmid expressing wild type CHL1 (C–E) or FIGAA mutant
CHL1 (F–H). A, differential interference contrast image of HEK293
cells transfected with the ankyrin-GFP construct alone. B, HEK293
cells shown in A expressed ankyrin-GFP with a diffuse cytoplasmic
localization. C, differential interference contrast image of cells co-trans-
fected with the wild type CHL1 and ankyrin-GFP constructs. D,
ankyrin-GFP was recruited to the membrane of cells expressing wild
type CHL1, shown in C. E, CHL1 was localized on the cell membranes,
as shown by immunofluorescence of cells in C using CHL1 antibodies
and TRITC-conjugated secondary antibody. F, differential interference
contrast image of cells co-transfected with the CHL1 FIGAA mutant
and ankyrin-GFP constructs. G, ankyrin-GFP was not recruited to the
membrane of cells expressing the mutant CHL1, shown in F, and
assumes the same diffuse cytoplasmic localization as in cells not ex-
pressing CHL1 (B). H, the FIGAA mutant was normally inserted in the
plasma membrane.
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cell surface, and a DGEA motif in the Ig6 domain was required
for enhancing migration. Through a key tyrosine residue in the
FIGAY sequence within the CHL1 cytoplasmic domain, CHL1
was able to recruit ankyrin, an adapter for the spectrin-actin
cortical skeleton, suggesting that this capacity was necessary
for the promotion of integrin-dependent migration.
Our results describing the functional interaction of CHL1
with 1 integrins are consistent with a model in which CHL1
associates with 1 integrins in cis on the plasma membrane to
promote cell migration on extracellular matrix substrates (Fig.
7). A direct or indirect association between CHL1 and 1 inte-
grins is supported by their ability to co-cap on the cell surface
upon antibody-induced cross-linking. A potential integrin in-
teraction motif, the DGEA sequence in the Ig6 domain of
CHL1, was necessary for potentiating migration to collagen I,
but it was not essential for co-capping of CHL1 and 1 integrin.
Other determinants within the CHL1 protein thus may be
more important in the association with 1 integrin, although
DGEA or conformational elements of the Ig6 domain may con-
tribute to the interaction. L1 (36, 37, 61–64) and NrCAM (65)
also cooperate functionally with 1 integrins, although a phys-
ical association has only been reported for L1 (64). Like CHL1,
the Ig6 domain in L1 is important for enhancing migration, but
in the case of L1, an intrinsic RGD sequence in this domain is
the critical motif in promoting migration on fibronectin (37).
Although CHL1 contains an RGD domain located in the second
Ig domain (22), our experiments showed that the mutation of
this sequence did not affect the ability of CHL1 to potentiate
migration through 11 or 21 integrins.
CHL1 and L1 are closely related structurally, but they have
different effects in regulating haptotactic migration toward
extracellular matrix proteins. CHL1 promoted migration of
HEK293 cells toward collagen I through the collagen receptors
11 and 21 integrins, but L1 did not promote migration to
collagen I. Although both cell adhesion molecules stimulated
migration to fibronectin, L1-potentiated migration is strongly
inhibited by function blocking antibodies against the fibronec-
tin receptor, 51 integrin (37), whereas CHL1-potentiated mi-
gration to fibronectin was not affected substantially by these
antibodies.2 It is not known whether CHL1 promotes migration
toward other matrix substrates such as fibronectin, laminin, or
vitronectin through interactions with other integrin subtypes
or alternatively through integrin cross-talk (43, 66, 67). An
interesting possibility is that different L1 family members may
interact with distinct or overlapping subclasses of integrins to
potentiate haptotactic migration on diverse extracellular ma-
trix substrates.
CHL1-potentiated migration of HEK293 cells to extracellu-
lar matrix proteins depended on c-Src, PI 3-kinase, and MAP
kinase. These kinases are components of an early integrin
signaling pathway that elicits membrane ruffling and lamelli-
podia formation and enhances cell migration (68–70). Because
L1-potentiated migration also relies on these intermediates
(37), they may be sites for integration of signaling by L1 cell
adhesion molecules and integrins. Although we do not know
whether CHL1 can directly activate these kinases, their cata-
lytic function was necessary for enhancing migration. c-Src
may act in this capacity through its ability to down-regulate
RhoA GTPase, which has been shown to be necessary for inte-
grin-mediated cell migration (71). Targets of MAP kinase in-
volved in CHL1-stimulated cell migration have not been iden-
tified, but a possible candidate is myosin light chain kinase,
which is required for FG carcinoma cell motility on collagen
(72). CHL1-stimulated migration also relied in part on the
activity of PI 3-kinase, an enzyme that could contribute to cell
motility through its ability to influence integrin endocytosis
and recycling (49, 73).
The process of cell migration requires dynamic regulation of
cell adhesion through coupling of adhesion receptors with the
cytoskeleton (74, 75). The motif FIGQY in the cytoplasmic
domain motif of all L1 family members except CHL1 is part of
the binding site for ankyrin, a multivalent adapter of the spec-
trin/actin cortical skeleton (18). Although CHL1 possesses a
cytoplasmic motif, FIGAY, with a nonconservative substitu-
tion, our experiments show that CHL1 recruited ankyrin to the
cell membrane and that this motif was essential for potentiated
cell migration. This result suggested that ankyrin binding may
play a role in the mechanism of cell migration, although other
functions of the CHL1 cytoplasmic domain might be perturbed
by this mutation, accounting for the abrogation of migration. In
any case, ankyrin-binding domains of L1 family members do
not have an absolute requirement in regard to sequence spec-
ificity. Several studies have shown that the association of L1
family members with ankyrin is regulated by tyrosine phos-
phorylation of the FIGQY sequence (54, 76) and that mutations
of the conserved tyrosine perturb the ankyrin-binding function
(38, 58). It is not known whether the tyrosine within the FIGAY
sequence of CHL1 is phosphorylated, but its importance is
evident from the perturbation of both ankyrin recruitment and
enhancement of haptotactic cell migration toward extracellular
2 M. Buhusi, B. R. Midkiff, A. M. Gates, M. Richter, M. Schachner,
and P. F. Maness, unpublished data.
FIG. 7. Hypothetical model of the molecular interactions in-
volved in CHL1-potentiated migration through 1 integrins.
CHL1 interacts with 1/21 integrins in cis on the cell surface and
promotes intracellular signaling through c-Src, PI 3-kinase, and MAP
kinase, which stimulates cell migration on extracellular matrix (ECM)
proteins such as collagen I. The CHL1 Ig6 domain, including the DGEA
motif, may transiently interact with a binding site on 1 integrins to
stimulate cell signaling, but it is not sufficient for the interaction.
Linkage of CHL1 to the actin cytoskeleton through ankyrin binding to
the FIGAY sequence is necessary for enhanced cell motility and may
stabilize adhesive contacts with the substrate.
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matrix proteins when it is mutated to an alanine residue.
CHL1 binding to the spectrin-actin skeleton may increase the
adhesion between the leading edge of the cell and substrate,
which could promote cell migration (74). Finally, it did not
appear that CHL1 required cell-cell contact for ankyrin bind-
ing. Although CHL1 is not known to engage in homophilic
binding, interaction with the extracellular matrix substrate
through cis integrin association could provide necessary con-
tact that may regulate ankyrin recruitment.
Taken together these results are consistent with a model
(Fig. 7) in which CHL1 interacts in cis with 11 and 21
integrins on the cell surface to promote intracellular signaling
through c-Src, PI 3-kinase, and MAP kinase, which stimulate
cell migration on extracellular matrix proteins such as collagen
I. The CHL1 Ig6 domain may transiently interact with a bind-
ing site on 1 integrins to stimulate cell signaling, but it is not
sufficient for the interaction. Linkage of CHL1 to the actin
cytoskeleton through ankyrin binding to the FIGAY sequence
is also an important determinant of cell motility and may help
stabilize adhesive contacts with the extracellular matrix
substrate.
The capacity of CHL1 to potentiate haptotactic migration
toward extracellular matrix proteins through integrins in these
in vitro studies may reflect a physiological role for CHL1 in
integrin-dependent cell migration during nerve regeneration.
CHL1 may regulate the migration of Schwann cells at sites of
nerve injury, because it is strongly up-regulated in Schwann
cells during regeneration (23). Schwann cell migration on re-
generating nerves is supported by collagens I, III, IV, and
fibronectin, which, along with 11 integrin, increase at the
injury site (41, 77, 78). CHL1 expression is also up-regulated in
dorsal root ganglion and thalamic neurons upon injury (23, 79)
and is a strong promoter of neurite growth (20), suggesting that
it may function analogously to promote axon growth on extra-
cellular matrix substrates. The ability of CHL1 to promote cell
migration toward extracellular matrix proteins may also play a
role in radial glia-guided migration of cortical neurons in the
developing neocortex, where integrin receptors and their
ligands are distributed (80) and CHL1 is prominently ex-
pressed (21).
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